Katherine J. Aitchison

List of Publications by Year
in descending order

178 papers	9,873 citations	30551 56 h-index	46524 93 g-index
202 all docs	202 docs citations	202 times ranked	12857 citing authors

#	Article	IF	Citations
1	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	1.0	31
2	*CYP2D6* and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 33-45.	0.7	15
3	Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?. Canadian Journal of Psychiatry, 2021, 66, 185-194.	0.9	7
4	Mobile App–Based Self-Report Questionnaires for the Assessment and Monitoring of Bipolar Disorder: Systematic Review. JMIR Formative Research, 2021, 5, e13770.	0.7	9
5	Sequence2Script: A Web-Based Tool for Translation of Pharmacogenetic Data Into Evidence-Based Prescribing Recommendations. Frontiers in Pharmacology, 2021, 12, 636650.	1.6	22
6	Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds. Frontiers in Pharmacology, 2021, 12, 713178.	1.6	2
7	Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials. Journal of Psychiatric Research, 2021, 140, 267-281.	1.5	22
8	Internal consistency and concurrent validity of self-report components of a new instrument for the assessment of suicidality, the Suicide Ideation and Behavior Assessment Tool (SIBAT). Psychiatry Research, 2021, 304, 114128.	1.7	1
9	Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 2021, 54, 5-17.	1.7	96
10	Identification of high-impact gene–drug pairs for pharmacogenetic testing in Alberta, Canada. Pharmacogenetics and Genomics, 2021, 31, 29-39.	0.7	8
11	The feasibility and acceptability of mobile application-based assessment of suicidality using self-report components of a novel tool, the Suicide Ideation and Behavior Assessment Tool (SIBAT). Psychiatry Research, 2021, 307, 114316.	1.7	1
12	Methodology for clinical genotyping of CYP2D6 and CYP2C19. Translational Psychiatry, 2021, 11, 596.	2.4	15
13	Dimensions of temperament and character as predictors of antidepressant discontinuation, response and adverse reactions during treatment with nortriptyline and escitalopram. Psychological Medicine, 2021, , 1-9.	2.7	3
14	Decreased Medial Prefrontal Cortex Glutamate Levels in Perimenopausal Women. Frontiers in Psychiatry, 2021, 12, 763562.	1.3	6
15	A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression. Molecular Psychiatry, 2020, 25, 1312-1322.	4.1	20
16	Reply to Dawes et al.. Canadian Journal of Psychiatry, 2020, 65, 586-587.	0.9	0
17	Pharmacogenomics and Psychopharmacology. , 2020, , 151-202.		2
18	Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. Canadian Journal of Psychiatry, 2020, 65, 521-530.	0.9	32

#	Article	IF	Citations
19	Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. Frontiers in Psychiatry, 2020, 11, 94.	1.3	74
20	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. Frontiers in Genetics, 2020, 11, 491895.	1.1	28
21	T75GWAS AND PATHWAY ENRICHMENT ANALYSIS IN ADVERSE DRUG REACTIONS IN DEPRESSION. European Neuropsychopharmacology, 2019, 29, S255-S256.	0.3	0
22	Trend level gene-gender interaction effect for the BDNF rs6265 variant on age of onset of psychosis. Psychiatry Research, 2019, 280, 112500.	1.7	5
23	F93. CYP2D6 Revisited in GENDEP, a Multicenter Clinical Trial of Nortriptyline and Escitalopram. Biological Psychiatry, 2019, 85, S248-S249.	0.7	0
24	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. British Journal of Psychiatry, 2019, 215, 494-501.	1.7	10
25	Differential gene expression analysis in blood of first episode psychosis patients. Schizophrenia Research, 2019, 209, 88-97.	1.1	27
26	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	1.1	7
27	Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma. Frontiers in Psychiatry, 2019, 10, 808.	1.3	133
28	Prediction and Understanding of Resilience in Albertan Families: Longitudinal Study of Disaster Responses (PURLS) â€" Protocol. Frontiers in Psychiatry, 2019, 10, 729.	1.3	3
29	Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. Scientific Reports, 2018, 8, 5530.	1.6	51
30	Implications of Cannabis Legalization on Youth and Young Adults. Canadian Journal of Psychiatry, 2018, 63, 65-71.	0.9	17
31	New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics Journal, 2018, 18, 413-421.	0.9	40
32	Contribution of genes in the GABAergic pathway to bipolar disorder and its executive function deficit in the Chinese Han population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 50-67.	1.1	4
33	Associations between the <i>LEP</i> -2548G/A Promoter and Baseline Weight and between <i>LEPR</i> Gln223Arg and Lys656Asn Variants and Change in BMI <i>z</i> Scores in Arab Children and Adolescents Treated with Risperidone. Molecular Neuropsychiatry, 2018, 4, 111-117.	3.0	5
34	F190. EFFECT OF SELECTED GENE VARIANTS ON THE RELATIONSHIP BETWEEN EARLY CANNABIS USE AND AGE OF ONSET OF PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S295-S295.	2.3	0
35	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.3	64
36	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). Translational Psychiatry, 2018, 8, 150.	2.4	19

#	Article	IF	Citations
37	Genetic disposition to inflammation and response to antidepressants in major depressive disorder. Journal of Psychiatric Research, 2018, 105, 17-22.	1.5	18
38	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	2.5	71
39	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. Brain, Behavior, and Immunity, 2017, 62, 344-350.	2.0	202
40	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nature Communications, 2017, 8, 15497.	5.8	144
41	Investigation of the *COMT* Val158Met variant association with age of onset of psychosis, adjusting for cannabis use. Brain and Behavior, 2017, 7, e00850.	1.0	14
42	Interaction between the *FTO* gene, body mass index and depression: meta-analysis of 13701 individuals. British Journal of Psychiatry, 2017, 211, 70-76.	1.7	49
43	An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis. Biological Psychiatry, 2017, 81, 470-477.	0.7	176
44	Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram. European Neuropsychopharmacology, 2017, 27, S582-S583.	0.3	0
45	Interplay between Schizophrenia Polygenic Risk Score and Childhood Adversity in First-Presentation Psychotic Disorder: A Pilot Study. PLoS ONE, 2016, 11, e0163319.	1.1	52
46	Combining clinical variables to optimize prediction of antidepressant treatment outcomes. Journal of Psychiatric Research, 2016, 78, 94-102.	1.5	149
47	Transcriptomics and the mechanisms of antidepressant efficacy. European Neuropsychopharmacology, 2016, 26, 105-112.	0.3	19
48	Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. Schizophrenia Research, 2016, 170, 245-251.	1.1	6
49	Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder. Biological Psychiatry, 2016, 79, 329-336.	0.7	21
50	Familiality and SNP heritability of age at onset and episodicity in major depressive disorder. Psychological Medicine, 2015, 45, 2215-2225.	2.7	21
51	Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology, 2015, 232, 2609-2617.	1.5	31
52	Modulatory effects of brain-derived neurotrophic factor Val66Met polymorphism on prefrontal regions in major depressive disorder. British Journal of Psychiatry, 2015, 206, 379-384.	1.7	56
53	Authors' reply. British Journal of Psychiatry, 2015, 207, 363-364.	1.7	1
54	Role of a Combination of Seven Micronutrients in the Management of Glioblastoma Multiforme. Clinical Oncology, 2015, 27, 370-371.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophrenia Bulletin, 2015, 41, 1171-1182.	2.3	73
56	Neurological Structure Variations in Individuals with Autism Spectrum Disorder: a Review. Journal of Microbiology and Biotechnology, 2014, 24, 268-275.	0.9	3
57	Investigation of blood mRNA biomarkers for suicidality in an independent sample. Translational Psychiatry, 2014, 4, e474-e474.	2.4	24
58	The effect of age on DNA concentration from whole saliva: Implications for the standard isolation method. American Journal of Human Biology, 2014, 26, 859-862.	0.8	3
59	Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. Journal of Psychopharmacology, 2014, 28, 142-150.	2.0	18
60	Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. Journal of Psychopharmacology, 2014, 28, 133-141.	2.0	75
61	Genomics for clinical utility: the future is near. Genome Medicine, 2014, 6, 3.	3.6	4
62	P.2.a.021 Genome-wide association study of antidepressant-induced sexual dysfunction in depressed males. European Neuropsychopharmacology, 2014, 24, S373-S374.	0.3	0
63	Association of tardive dyskinesia with variation in <i>CYP2D6</i>: Is there a role for active metabolites?. Journal of Psychopharmacology, 2014, 28, 665-670.	2.0	21
64	Association of KIBRA rs17070145 polymorphism with episodic memory in the early stages of a human neurodevelopmental disorder. Psychiatry Research, 2014, 220, 37-43.	1.7	12
65	Effects of antidepressant drug exposure on gene expression in the developing cerebral cortex. Synapse, 2014, 68, 209-220.	0.6	10
66	NPAS3 variants in schizophrenia: a neuroimaging study. BMC Medical Genetics, 2014, 15, 37.	2.1	1
67	Relationship between obesity and the risk of clinically significant depression: Mendelian randomisation study. British Journal of Psychiatry, 2014, 205, 24-28.	1.7	62
68	Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophrenia Research, 2014, 157, 84-89.	1.1	50
69	Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics Journal, 2014, 14, 395-399.	0.9	20
70	Genome-wide association analysis of copy number variation in recurrent depressive disorder. Molecular Psychiatry, 2013, 18, 183-189.	4.1	45
71	Duration of untreated psychosis in adolescents: Ethnic differences and clinical profiles. Schizophrenia Research, 2013, 150, 526-532.	1.1	35
72	Benzodiazepines: Risks and benefits. A reconsideration. Journal of Psychopharmacology, 2013, 27, 967-971.	2.0	177

#	Article	IF	Citations
73	Genome‐wide association analysis accounting for environmental factors through propensity‐score matching: Application to stressful live events in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 521-529.	1.1	16
74	Serum and gene expression profile of cytokines in first-episode psychosis. Brain, Behavior, and Immunity, 2013, 31, 90-95.	2.0	174
75	Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. European Neuropsychopharmacology, 2013, 23, 1105-1114.	0.3	68
76	P.4.002 Genetic differences in drug-metabolising enzymes: can they be used to predict antidepressant treatment response?. European Neuropsychopharmacology, 2013, 23, S69-S70.	0.3	0
77	Modulation of amygdala response and connectivity in depression by serotonin transporter polymorphism and diagnosis. Journal of Affective Disorders, 2013, 150, 96-103.	2.0	70
78	Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis. Paediatric Drugs, 2013, 15, 139-150.	1.3	122
79	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. American Journal of Psychiatry, 2013, 170, 207-217.	4.0	216
80	Reply to 'MDMA can increase cortical levels by 800% in dance clubbers' Parrott et al.. Journal of Psychopharmacology, 2013, 27, 115-116.	2.0	4
81	Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline 'Predictors' and Longitudinal 'Targets'. Neuropsychopharmacology, 2013, 38, 377-385.	2.8	372
82	Ecstasy, legal highs and designer drug use: A Canadian perspective. Drug Science, Policy and Law, 2013, 1, 205032451350919.	0.6	5
83	Ethnic variations in pathways into early intervention services for psychosis. British Journal of Psychiatry, 2013, 202, 277-283.	1.7	46
84	Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. Journal of Psychopharmacology, 2012, 26, 419-428.	2.0	33
85	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. PLoS Medicine, 2012, 9, e1001326.	3.9	110
86	Can genetics inform the management of cognitive deficits in schizophrenia?. Journal of Psychopharmacology, 2012, 26, 334-348.	2.0	9
87	CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. Journal of Psychopharmacology, 2012, 26, 398-407.	2.0	69
88	Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. Journal of Psychopharmacology, 2012, 26, 408-418.	2.0	17
89	Special issue on Pharmacogenetics. Journal of Psychopharmacology, 2012, 26, 333-333.	2.0	0
90	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychological Medicine, 2012, 42, 967-980.	2.7	298

#	Article	IF	Citations
91	P.2.c.028 Candidate genes expression profile associated with antidepressants response: baseline predictors and longitudinal targets. European Neuropsychopharmacology, 2012, 22, S266-S267.	0.3	0
92	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics Journal, 2012, 12, 68-77.	0.9	92
93	Dissecting the Genetic Heterogeneity of Depression Through Age at Onset. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 859-868.	1.1	31
94	White matter abnormalities and illness severity in major depressive disorder. British Journal of Psychiatry, 2012, 201, 33-39.	1.7	126
95	Depressive disorder moderates the effect of the FTO gene on body mass index. Molecular Psychiatry, 2012, 17, 604-611.	4.1	72
96	Reduced Anxiety and Depression-Like Behaviours in the Circadian Period Mutant Mouse Afterhours. PLoS ONE, 2012, 7, e38263.	1.1	54
97	Convergent Animal and Human Evidence Suggests a Role of PPM1A Gene in Response to Antidepressants. Biological Psychiatry, 2011, 69, 360-365.	0.7	30
98	Genomewide Association Scan of Suicidal Thoughts and Behaviour in Major Depression. PLoS ONE, 2011, 6, e20690.	1.1	98
99	Antidepressants and the resilience to early-life stress in inbred mouse strains. Pharmacogenetics and Genomics, 2011, 21, 779-789.	0.7	28
100	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. Journal of Affective Disorders, 2011, 132, 112-120.	2.0	93
101	Changes in body weight during pharmacological treatment of depression. International Journal of Neuropsychopharmacology, 2011, 14, 367-375.	1.0	41
102	Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of Psychopharmacology, 2011, 25, 867-874.	2.0	44
103	Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis. Journal of Psychopharmacology, 2011, 25, 675-684.	2.0	5
104	Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychological Medicine, 2011, 41, 463-476.	2.7	102
105	Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2011, 11, 138-145.	0.9	70
106	Pharmacogenetics of antidepressant response. Expert Review of Neurotherapeutics, 2011, 11, 101-125.	1.4	45
107	Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the *5-HTTLPR*. World Journal of Biological Psychiatry, 2011, 12, 528-538.	1.3	31
108	Early and Delayed Onset of Response to Antidepressants in Individual Trajectories of Change During Treatment of Major Depression. Journal of Clinical Psychiatry, 2011, 72, 1478-1484.	1.1	117

#	Article	IF	Citations
109	Stress and Inflammation Reduce Brain-Derived Neurotrophic Factor Expression in First-Episode Psychosis. Journal of Clinical Psychiatry, 2011, 72, 1677-1684.	1.1	245
110	History of suicide attempts among patients with depression in the GENDEP project. Journal of Affective Disorders, 2010, 123, 131-137.	2.0	18
111	Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. Journal of Affective Disorders, 2010, 127, 337-342.	2.0	32
112	Clinical lessons from GENDEP for the treatment of depression. Annals of General Psychiatry, 2010, 9, .	1.2	0
113	Regional distribution of clomipramine and desmethylclomipramine in rat brain and peripheral organs on chronic clomipramine administration. Journal of Psychopharmacology, 2010, 24, 1261-1268.	2.0	15
114	Genome-Wide Association Study of Major Recurrent Depression in the U.K. Population. American Journal of Psychiatry, 2010, 167, 949-957.	4.0	221
115	Trajectories of change in depression severity during treatment with antidepressants. Psychological Medicine, 2010, 40, 1367-1377.	2.7	107
116	Letter to the Editor: Further evidence is required to confirm association between CACNA1C gene variants and bipolar affective disorder. Psychological Medicine, 2010, 40, 702-704.	2.7	1
117	Gender differences in antidepressant drug response. International Review of Psychiatry, 2010, 22, 485-500.	1.4	139
118	Housekeeping gene expression is affected by antidepressant treatment in a mouse fibroblast cell line. Journal of Psychopharmacology, 2010, 24, 1253-1259.	2.0	18
119	Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project. American Journal of Psychiatry, 2010, 167, 555-564.	4.0	314
120	Phospholipase A2 and Cyclooxygenase 2 Genes Influence the Risk of Interferon-α–Induced Depression by Regulating Polyunsaturated Fatty Acids Levels. Biological Psychiatry, 2010, 67, 550-557.	0.7	160
121	DOES STRESS CONTRIBUTE TO INFLAMMATORY AND METABOLIC ABNORMALITIES IN FIRST EPISODE PSYCHOSIS?. Schizophrenia Research, 2010, 117, 369-370.	1.1	0
122	The genetics of affective disorder and suicide. European Psychiatry, 2010, 25, 275-277.	0.1	55
123	Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. Schizophrenia Research, 2010, 116, 234-242.	1.1	253
124	Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophrenia Research, 2010, 119, 75-78.	1.1	112
125	No association between genetic markers inBDNFgene and lithium prophylaxis in a Greek sample. International Journal of Psychiatry in Clinical Practice, 2010, 14, 154-157.	1.2	7
126	Disclosure of religious beliefs. British Journal of Psychiatry, 2009, 195, 368-368.	1.7	0

#	ARTICLE	IF	CITATIONS
127	Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding. Psychological Medicine, 2009, 39, 1231-1235.	2.7	18
128	A UK consensus on the administration of aripiprazole for the treatment of mania. Journal of Psychopharmacology, 2009, 23, 231-240.	2.0	21
129	Adverse reactions to antidepressants. British Journal of Psychiatry, 2009, 195, 202-210.	1.7	205
130	Moderation of antidepressant response by the serotonin transporter gene. British Journal of Psychiatry, 2009, 195, 30-38.	1.7	143
131	Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial. BMC Medicine, 2009, 7, 60.	2.3	43
132	Body weight as a predictor of antidepressant efficacy in the GENDEP project. Journal of Affective Disorders, 2009, 118, 147-154.	2.0	89
133	Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment. Molecular Psychiatry, 2009, 14, 1095-1104.	4.1	214
134	Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2009, 9, 225-233.	0.9	188
135	Genetic Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in the GENDEP Project. Neuropsychopharmacology, 2009, 34, 2517-2528.	2.8	105
136	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. British Journal of Psychiatry, 2009, 194, 252-259.	1.7	170
137	Pharmacogenetics of antidepressant response. , 2009, , 299-314.		3
138	Routine evaluation in first episode psychosis services: feasibility and results from the MiData project. Social Psychiatry and Psychiatric Epidemiology, 2008, 43, 960-967.	1.6	49
139	Duration of Untreated Psychosis, Referral Route, and Age of Onset in an Early Intervention in Psychosis Service and a Local CAMHS. Child and Adolescent Mental Health, 2008, 13, 130-133.	1.8	15
140	Change in sexual dysfunction with aripiprazole: a switching or add-on study. Journal of Psychopharmacology, 2008, 22, 244-253.	2.0	75
141	Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. Journal of Psychopharmacology, 2008, 22, 323-329.	2.0	34
142	Measuring depression: comparison and integration of three scales in the GENDEP study. Psychological Medicine, 2008, 38, 289-300.	2.7	227
143	Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. Journal of Psychopharmacology, 2006, 20, 400-410.	2.0	96
144	TC2C USE OF CANNABIS IN A EAST-LONDON FIRST EPISODE PSYCHOSIS SAMPLE: DATA FROM THE GAP â€" GENETICS AND PSYCHOSIS â€" STUDY. Schizophrenia Research, 2006, 86, S26.	1.1	0

#	ARTICLE	IF	CITATIONS
145	0508 PATHWAYS TO CARE FOR TREATMENT OF YOUNG ADULTS WITH A PSYCHOTIC ILLNESS IN SOUTH LONDON. Schizophrenia Research, 2006, 86, S126.	1.1	1
146	0515 ARIPIPRAZOLE SWITCHING STRATEGIES IN COMMUNITY PATIENTS WITH PSYCHOSIS. Schizophrenia Research, 2006, 86, S134.	1.1	1
147	Comments on "Prolactin Levels and Erectile Function in Patients Treated With Risperidone" (J Clin) Tj ETQq1 1 0.784314 rgBT /Overlo	0.7	1
148	Pharmacogenetics: antidepressant drug response. Psychiatry (Abingdon, England), 2005, 4, 30-34.	0.2	3
149	The genetics of depression and related traits. Current Psychiatry Reports, 2005, 7, 117-124.	2.1	21
150	Psychiatry and the 'new genetics': hunting for genes for behaviour and drug response. British Journal of Psychiatry, 2005, 186, 91-92.	1.7	15
151	Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Current Medical Research and Opinion, 2004, 20, 1649-1649.	0.9	5
152	Clinical relevance of discoveries in psychopharmacogenetics1. Advances in Psychiatric Treatment, 2004, 10, 455-465.	0.6	3
153	Early intervention in psychosis: from Government prescription to clinical practice. Psychiatric Bulletin, 2003, 27, 243-244.	0.3	2
154	Pharmacogenetics in the postgenomic era.. , 2003, , 335-361.		7
155	Clozapine response and genetic variation in neurotransmitter receptor targets. , 2002, , 217-244.		0
156	Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics and Genomics, 2000, 10, 43-48.	5.7	82
157	Identification of novel polymorphisms in the 5'flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics and Genomics, 2000, 10, 695-704.	5.7	35
158	THE RELEVANCE OF ETHNIC INFLUENCES ON PHARMACOGENETICS TO THE TREATMENT OF PSYCHOSIS. Drug Metabolism and Drug Interactions, 2000, 16, 15-38.	0.3	27
159	Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice. Journal of Psychopharmacology, 2000, 14, 353-359.	2.0	39
160	The pharmaco-economics of atypical antipsychotics. International Journal of Psychiatry in Clinical Practice, 1999, 3, 237-248.	1.2	12
161	Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. British Journal of Clinical Pharmacology, 1999, 48, 388-394.	1.1	34
162	Association analysis between dopamine receptor genes and bipolar affective disorder. Psychiatry Research, 1999, 86, 193-201.	1.7	51

#	Article	IF	Citations
163	CYP2D6 polymorphisms in Alzheimer's disease, with and without extrapyramidal signs, showing no apoloprotein E Iμ4 effect modification. Biological Psychiatry, 1999, 45, 426-429.	0.7	19
164	Apolipoprotein E: Depressive illness, depressive symptoms, and Alzheimer's disease. Biological Psychiatry, 1998, 43, 159-164.	0.7	44
165	Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia. Schizophrenia Research, 1998, 32, 87-92.	1.1	39
166	Cost-effectiveness of clozapine. British Journal of Psychiatry, 1997, 171, 125-130.	1.7	86
167	Pharmacogenetic factors in treatment-resistant schizophrenia: The role of CYP2D6 variants. Schizophrenia Research, 1997, 24, 89.	1.1	0
168	Allelic variation of the 5-HT2C receptor in psychosis. Schizophrenia Research, 1997, 24, 90-91.	1.1	0
169	No evidence for an association of affective disorders with high- or low-activity allele of catechol-o-methyltransferase gene. Biological Psychiatry, 1997, 42, 282-285.	0.7	101
170	Allelic association between a ser-9-gly polymorphism in the D3 receptor gene and schizophrenia. Schizophrenia Research, 1996, 18, 163.	1.1	0
171	No Association between Parkinson's Disease and Low-Activity Alleles of CatecholO-Methyltransferase. Biochemical and Biophysical Research Communications, 1996, 228, 780-784.	1.0	83
172	Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Human Genetics, 1996, 97, 714-719.	1.8	141
173	The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. NeuroReport, 1996, 7, 1675-1679.	0.6	190
174	Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Human Genetics, 1996, 97, 714-719.	1.8	12
175	Cytochrome P4502D6 genotype does not determine response to clozapine.. British Journal of Clinical Pharmacology, 1995, 39, 417-420.	1.1	65
176	Homozygous osteogenesis imperfecta unlinked to collagen I genes. Human Genetics, 1988, 78, 233-236.	1.8	64
177	An RFLP close to the human collagen I gene COL1AI. Nucleic Acids Research, 1987, 15, 4699-4699.	6.5	11
178	Biological treatments: general considerations. , 0, , 567-585.		0